Stock Taper 
AYTU
$2.21
▼ DOWN 3.28% (-0.07)
KEY STATISTICS
Market Cap$23.72 M
52w High$3.07
52w Low$1.65
Dividend Yield—
Frequency—
P/E-1.15
Volume15.76K
Shares Out.10.73M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Joshua R. Disbrow
COMPENSATION 2026
Salary$590,000
Stock Awards$0
Incentive Plan Pay$247,800
All Other Comp.$0
Total$883,928
ABOUT
SECTOR
Healthcare
WENT PUBLIC
September 25, 2008
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
83
UPCOMING EARNINGS
DateSep 22, 2026
DayTuesday
Rev. Est.$17.18M
SEP
22
TUE
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-01-06 | Reverse | 1:20 |
| 2020-12-09 | Reverse | 1:10 |
| 2018-08-13 | Reverse | 1:20 |
| 2017-08-29 | Reverse | 1:20 |
| 2016-10-28 | Reverse | 1:12 |
| 2016-07-01 | Reverse | 1:12 |
| 2015-08-17 | Reverse | 41:500 |
| 2015-06-10 | Reverse | 41:500 |
PRICE
$2.21 ▼ DOWN 3.28% (−$0.07)About Aytu BioPharma, Inc.
https://aytubio.com ↗Aytu Biopharma, Inc. develops and markets innovative prescription and consumer healthcare products, including ADHD treatments, allergy remedies, and sleep aids, serving the U.S. and international markets.
INDUSTRY
Drug Manufacturers - Specialty & Generic
A PRODUCT AYTU BIOPHARMA, INC. IS KNOWN FOR
EXXUA™ (gepirone) extended-release tablets
EXXUA™, FDA-approved in 2025, is the first selective serotonin 5HT1a receptor agonist for adult MDD, marking Aytu BioPharma's entry into the $multi-billion U.S. antidepressant market with a novel treatment and distinct side effect profile.
Revenue by Products
| Icon | PRODUCT | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|---|
 | Consumer Health | — | $4.19M | $3.97M ▼ | $11.85M ▲ |
 | Pediatric | $2.56M | — | — | — |
 | Other | $124K | — | — | — |
Revenue by Geography
| Map | REGION | Q3-2022 | Q4-2022 | Q1-2023 | Q4-2023 |
|---|---|---|---|---|---|
 | UNITED STATES | — | $27.2M | $27.48M ▲ | $79.44M ▲ |
| U S | $23.75M | — | — | — |
 | NonUS | — | $250K | $179K ▼ | $302K ▲ |
ETFS HOLDING THIS STOCK
ETFS HOLDING
16
LISTED HERE
3
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
36.06%
HOLDERS
48
TOP 12 OF 48 · RANKED BY POSITION SIZE
Nantahala Capital Management, LLC
Stonepine Capital Management, LLC
Awm Investment Company, Inc.
Diadema Partners LP
Vanguard Group Inc
Crown Advisors Management, Inc.
Two Sigma Investments, LP
Renaissance Technologies LLC
Persistent Asset Partners Ltd
Geode Capital Management, LLC
Arete Wealth Advisors, LLC
Dimensional Fund Advisors LP
RATINGS SNAPSHOT
Overall rating: C
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score2
INSIDER TRADES
★
DIRECTOR
LIU VIVIAN H
Purchase · 10.0K shares
2026-07-28
★
OFFICER: CHIEF COMMERCIAL OFFICER
PYSZCZYMUKA GREG
Purchase · 20.0K shares
2026-07-28
★
OFFICER: CHIEF FINANCIAL OFFICER
Selhorn Ryan J
Purchase · 25.0K shares
2026-07-28
★
DIRECTOR
DOCKERY CARL
Purchase · 10.0K shares
2026-07-28
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 ANL | $15.01 | COMPARE |
 TXMD | $2.21 | COMPARE |
 BFRI | $1.61 | COMPARE |
 OSRH | $0.12 | COMPARE |
 GOVX | $0.48 | COMPARE |
 PRPH | $0.02 | COMPARE |
 NVNO | $11.44 | COMPARE |